Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical Products Agency.

Kälkner, Karl Mikael; Sundström, Anders; Nurminen, Marja-Leena; Larsson, Maria; Ljung, Rickard; Arthurson, Veronica

Kälkner, Karl Mikael; Sundström, Anders; Nurminen, Marja-Leena; Larsson, Maria; Ljung, Rickard; Arthurson, Veronica.

Kälkner KM; Division of Use and Information, Swedish Medical Products Agency, PO Box 26, 751 03, Uppsala, Sweden. karl-mikael.kalkner@lakemedelsverket.se.
Sundström A; Division of Use and Information, Swedish Medical Products Agency, PO Box 26, 751 03, Uppsala, Sweden.
Nurminen ML; Division of Use and Information, Swedish Medical Products Agency, PO Box 26, 751 03, Uppsala, Sweden.
Larsson M; Division of Use and Information, Swedish Medical Products Agency, PO Box 26, 751 03, Uppsala, Sweden.
Ljung R; Division of Use and Information, Swedish Medical Products Agency, PO Box 26, 751 03, Uppsala, Sweden.
Arthurson V; Division of Use and Information, Swedish Medical Products Agency, PO Box 26, 751 03, Uppsala, Sweden.

Drug Saf ; 46(3): 319-321, 2023 03.

Article in English | MEDLINE | ID: covidwho-2241956

Subject(s)

COVID-19 Vaccines; COVID-19; Vaccines; Humans; COVID-19/prevention & control; COVID-19 Vaccines/adverse effects; Product Surveillance, Postmarketing; SARS-CoV-2; Sweden/epidemiology; Vaccination

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Vaccines / COVID-19 Type of study: Observational study Topics: Vaccines Limits: Humans Country/Region as subject: Europa Language: English Journal: Drug Saf Journal subject: Drug Therapy / Toxicology Year: 2023 Document Type: Article Affiliation country: S40264-023-01275-7

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google